PBYI — Puma Biotechnology Inc

Is PBYI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Neutral As of August 19, 2026

Puma Biotechnology Inc (PBYI) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $9.24. The rating moved from Overbought to Neutral on August 14, 2026.

AI analysis

Puma Biotechnology Inc (PBYI) is a small-cap oncology company with valuation and near-term share performance tightly linked to clinical/regulatory developments and limited commercial diversification. Financial health is sensitive to cash burn and external financing; absent clear, near-term positive filings the balance of drivers is mixed. Market-driven risk-on flows can provide episodic support, but persistent reimbursement, competition, or trial setbacks would likely compress the share price. Monitor upcoming clinical milestones, cash runway disclosures, partnership or licensing activity, and any EDGAR filings for clearer directional signals.

Key factors

  • Concentrated revenue and product exposure: core commercial revenue historically tied to neratinib (Nerlynx) and limited marketed-product diversification.
  • Clinical & regulatory pathway drives valuation: near‑term value sensitive to trial readouts, label expansions or regulatory actions for oncology assets.
  • Capital structure and cash runway uncertainty: small-cap biotech with history of cash burn and potential need for dilution or financing, pressuring share volatility.
  • Market sentiment and risk-on flows: recent intraday risk-on tone for growth/biotech can support upside in short windows, but is fragile and news-driven.
  • Limited publicly-available near-term catalysts in filings: absence of fresh EDGAR filings in the provided dataset increases uncertainty about imminent positive disclosures.

Risks

  • Clinical development failure or delayed trial readouts for pipeline candidates, causing steep share declines.
  • Payer and reimbursement pressure reducing uptake or pricing for marketed products.
  • Cash runway shortfall leading to equity dilution or unfavorable financing terms.
  • Regulatory setbacks, label restrictions, or adverse safety findings for oncology assets.
  • Competition from larger oncology franchises and potential loss of market share.
  • Macroeconomic or geopolitical shocks that reverse risk-on flows and compress small-cap biotech liquidity.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for PBYI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.